Variation in antiviral immunity and inflammation pathways precedes HIV-1 infection in a high-risk African cohort
This work was supported by a Wellcome Trust Award (209289/Z/17/Z) and the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE) through the DELTAS Africa programme [Del-22-007], supported by the Science for Africa Foundation, Wellcome Trust, the UK Foreign, Commonwealth & Development Office, and the European Union. Additional support was provided by the Bill & Melinda Gates Foundation, Gilead Sciences Inc., Aidsfonds, and the Ragon Institute of Mass General, MIT, and Harvard. The cohort study was supported by PEPFAR through USAID. The views expressed are those of the authors.
Authors
- T. Ndung'u
- Philip Bejon
- Shaban Mwangi (ORCID: https://orcid.org/0000-0003-1961-3205)
- Jason T. Blackard (ORCID: https://orcid.org/0000-0003-2876-3811)
- Amin S. Hassan (ORCID: https://orcid.org/0000-0001-5296-4264)
- Eunice Wambui Nduati (ORCID: https://orcid.org/0000-0001-7578-3095)
- Mwikali Kioko
- Lynn Fwambah
- Abdirahman I. Abdi
- Eduard J. Sanders
Institutions
- Kenya Medical Research Institute (KE)
- Aurum Institute (ZA)
- Africa Health Research Institute (ZA)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- Journal of Clinical Investigation
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1172/jci195172
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- United States Agency for International Development
- Bill and Melinda Gates Foundation
- Massachusetts General Hospital
- Gilead Sciences
- U.S. President’s Emergency Plan for AIDS Relief
- Wellcome Trust
- European Commission